Product
  • Product
  • Content
  • No products in the cart.
Select Page
Hotline: 400-686-0075

Guangzhou Ribo Biotechnology (RiboBio), founded by distinguished expert of China’s Thousand Talents Program Dr. Bill Zhang and Nobel Prize winner Dr. Craig Mello, is a leading nucleic acids molecular and cellular biotech company in China. As a high-tech enterprise of China Torch Program based on leading nucleic acid technology, RiboBio provides a wide range of reagent products of nucleic acids and cellular research, services of scientific research, and CRO/CMO services and cGMP production of nucleic acid drugs. RiboBio is based at the development zone of Huangpu District, Guangzhou, and has built a national post-doctoral scientific research workstation in 2015.

Aiming to provide customers with the best nucleic acid technology and products, RiboBio has
a world-class scientific research team apart from a distinguished expert of China’s Thousand Talents Program and a Nobel Prize winner being the leaders. The core members of the company also include former CEO of Nasdaq-listed pharmaceutical company, tenured professor Dr. Tony Ip at the University of Massachusetts Medical School, as well as a group of outstanding professionals with experience at large international pharmaceutical companies.In 2011, RiboBio’s R&D team topped the list of Innovative Research Teams of Guangdong Province. It has formed close relations with scientific research institutions worldwide relying on its gene silencing technology, and has undertaken a number of major national, provincial and city scientific and technological research projects. In addition, it has built an internationally advanced high-throughput screening technology platform for new drugs, bioinformatics technology platform, gene detection and sequencing technology platform, pre-clinical research platform for new drugs, high-throughput oligonucleic acid synthesis platform and GMP production line for oligonucleic acid drug substances, Asia’s first fourth human genome-wide siRNA library, and China’s first CFDA-issued cGMP oligonucleic acid production base.

RiboBio’s honors include High-Tech Enterprise of China Torch Program, Key Entrepreneur Team of Overseas Chinese by the Overseas Chinese Affairs Office of the State Council, National Postdoctoral Workstation, Innovative Research Team Introduced by Guangdong Province, High-Tech Enterprise of Guangdong Province, High-Tech Product of Guangdong Province, the 5th Batch of Postdoctoral Innovation Practice Base in Guangdong Province, the 2nd Batch of Post-doctoral Innovation Practice Base in Guangzhou City, and Gazelle Business of Guangzhou Development District. RiboBio was also appointed to establish an industry-academia-research consortium with Nanfang Hospital for translational medicine. Our certifications are under ISO13485:2003 and ISO9001:2008 management systems, and has obtained A-level management qualification.

RiboBio has an international R&D team, leading technology, cutting-edge equipment, advanced R&D platform and modern production base. Through the development and production of scientific and clinical oligonucleic products, we are able to conduct new generation high-throughput sequencing, advanced bioinformatics analysis, high-content screening, nucleic acid drug analysis and identification, and animal experiments, thus offering an ideal platform for PhD students.

Location: Science City, Development Zone, Guangzhou, China
Qualifications: PhD degree in biology, medicine, genetics, pharmacy and related subjects
If you are interested, please send your CVs to hr@ribobio.com

QQ
WeChat
Phone

Service hotline

400-686-0075


Message